, may indicate colitis . However, blood in the stools and/or fever may be because of other causes of gastrointestinal bleeding, such as infection or peptic ulcer disease or bleeding due to tumor . Cough may be due to an upper respiratory infection
Search Results
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Featured Updates to the NCCN Guidelines
John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, and Anita Engh
John A. Thompson
combination is clearly better than monotherapy,” Dr. Thompson noted. While the combination protects against squamous cell carcinoma, dual blockade can produce fever and chills that often require temporary treatment cessation, with lower doses on resumption of
Jimmie C. Holland
), spiritual or religious concerns, and physical problems (eg, breathing problems, constipation, fatigue, fever). Patients can complete the form while in a busy waiting room, and those who have a score of 4 or more (moderate or severe distress) should be
Jae Park
chemotherapy, serious toxicities are associated with immune activation. The main toxicity, explained Dr. Park, is cytokine release syndrome (CRS), which manifests similarly to sepsis and is characterized by fever, hypotension, capillary leak, respiratory
John A. Thompson
treated) was a much higher incidence of fever. The newest BRAF/MEK inhibitor combination therapy to receive FDA approval is vemurafenib/cobimetinib. The data behind this approval come from the coBRIM clinical trial. 11 , 12 Larkin et al 11 , 12
John A. Thompson
, peritoneal signs consistent with perforation, ileus, fever), permanently discontinue ipilimumab, evaluate for bowel perforation, consider endoscopy, and give steroids until improvement, then taper over 1 month. Incorporating PD1 Inhibitors
David C. Dale
Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 13 Pettengell R Gurney H Radford JA
Presenter: Patrick A. Brown
most rapidly within the first week of therapy, which is the high-risk period for CRS,” said Dr. Brown, who noted that CRS is characterized by fever, hypotension, respiratory compromise, and potentially coagulopathy. Neurologic toxicities are the second
Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, and James K. Schwarz
experienced disease control for 7 months with the combination of chemotherapy and sorafenib. Case Presentation A 65-year-old man presented to the emergency room who had experienced worsening pain in both calves during the past 2 to 3 weeks, fever and
Henry G. Kaplan
left posterior neck tumor was 3 cm. During the third week of treatment, the patient experienced rapid onset of a macular erythematous rash that quickly grew to cover approximately 90% of her body. This was accompanied by daily fevers ranging from 102
